Medication Adherence and Clinical Outcomes in Sarcoidosis

Status: Active_not_recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY

The goal of the study is to look at the relationship between how individuals with Sarcoidosis take the sarcoidosis medicines and how it affects the disease, to evaluate any factors that may make individuals not want to take the medicines, and to develop and refine ways to help support individuals with Sarcoidosis especially when it comes to the medicines. The overall hypothesis is higher medication adherence will be associated with better clinical outcomes in sarcoidosis. The investigators will enroll 150 patients with biopsy proven pulmonary sarcoidosis for at least one year who are on any oral treatment regimen for at least six months into a 12-month longitudinal study.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• At least 18 years of age.

• Physician diagnosis of Sarcoidosis.

• Biopsy proven pulmonary involvement of Sarcoidosis.

• On oral Sarcoidosis medications for at least 6 months.

• Permanently reside in Maryland or D.C.

• Fully vaccinated against COVID-19.

Locations
United States
Maryland
Johns Hopkins Bayview Asthma and Allergy Center
Baltimore
Johns Hopkins Greenspring Station
Timonium
Time Frame
Start Date: 2022-05-11
Completion Date: 2026-08-31
Participants
Target number of participants: 150
Sponsors
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Leads: Johns Hopkins University

This content was sourced from clinicaltrials.gov